B
Bhamini Rangnekar
Researcher at University of Otago
Publications - 6
Citations - 107
Bhamini Rangnekar is an academic researcher from University of Otago. The author has contributed to research in topics: Aerosolization & Bedaquiline. The author has an hindex of 4, co-authored 6 publications receiving 68 citations.
Papers
More filters
Journal ArticleDOI
The influence of surface active l-leucine and 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC) in the improvement of aerosolization of pyrazinamide and moxifloxacin co-spray dried powders.
TL;DR: The differences in the aerosolization behaviours of the pyrazinamide and moxifloxacin spray dried powders with and without excipients was a combination of difference in the surface morphology and surface composition.
Journal ArticleDOI
Development and characterization of high payload combination dry powders of anti-tubercular drugs for treating pulmonary tuberculosis.
Basanth Babu Eedara,Bhamini Rangnekar,Shubhra Sinha,C. S. Doyle,Alex Cavallaro,Shyamal C. Das +5 more
TL;DR: A combination powder formulation of PML has the potential to deliver a high drug dose to the site of infection resulting in efficient treatment.
Journal ArticleDOI
Inhalable Dry Powder of Bedaquiline for Pulmonary Tuberculosis: In Vitro Physicochemical Characterization, Antimicrobial Activity and Safety Studies.
Mohammad A.M. Momin,Mohammad A.M. Momin,Bhamini Rangnekar,Shubhra Sinha,Chen-Yi Cheung,Gregory M. Cook,Shyamal C. Das +6 more
TL;DR: Improved aerosolization may help to combat pulmonary tuberculosis by potentially reducing the side-effects of oral bedaquiline and the safety of the optimized inhalable powder in animal models is required.
Journal ArticleDOI
Bedaquiline containing triple combination powder for inhalation to treat drug-resistant tuberculosis.
TL;DR: This is the first study reporting the development of inhalable triple combination powder of bedaquiline, moxifloxacin and pyrazinamide with high aerosolization efficiency, which may help to deliver a high dose of these drugs to treat drug-resistant tuberculosis.
Journal ArticleDOI
Development and validation of a RP-HPLC method for simultaneous quantification of bedaquiline (TMC207), moxifloxacin and pyrazinamide in a pharmaceutical powder formulation for inhalation
TL;DR: A reversed phase HPLC method for simultaneous quantification of bedaquiline (TMC207), moxifloxacin and pyrazinamide in a pharmaceutical powder formulation for inhalation was developed and validated as discussed by the authors.